Female Hair Loss: the hormonal panel to run first

Female-pattern hair loss (FPHL, or androgenetic alopecia in women) rarely shows up alone. By the time a woman notices a widening part, a thinner ponytail, or more scalp visible under bathroom lighting, there is usually a stack of contributing signals — thyroid drift, low iron stores, shifting androgens, perimenopausal estrogen decline, or a stress-driven telogen effluvium riding on top of true pattern loss.

Treating FPHL without checking those inputs is how patients end up on 12 months of topical minoxidil with mediocre results and no idea why. A hormonal panel isn't a formality — it's the map.

Why hair loss in women is almost never one thing (and why that matters)

Male-pattern loss is largely a DHT and receptor-sensitivity story. Female-pattern loss is messier. The follicle miniaturization process is similar, but women are far more likely to have a second driver stacked on top: iron deficiency, subclinical hypothyroidism, PCOS-range androgens, postpartum shedding, or the estrogen cliff of perimenopause.

A 2020 review in Dermatologic Clinics put it plainly: workup for FPHL should routinely screen thyroid, iron, and androgen status, because comorbid contributors are the rule rather than the exception.

So when a clinician jumps straight to "try minoxidil for six months and see," they may be right about the drug — but they're leaving the second driver untreated.

The core panel: what actually belongs on the requisition (in plain English)

A thorough workup for a woman presenting with diffuse thinning or a widening midline part would typically include the following markers. Not every patient needs every one, but this is the shortlist worth having in front of a clinician before a serious protocol.

Thyroid

• TSH — the screening baseline. Even high-normal TSH (above ~2.5 mIU/L) is worth a second look if shedding is active.
• Free T4 and Free T3 — because TSH alone can miss conversion issues.
• TPO antibodies — Hashimoto's is common in women and drives diffuse shedding well before overt hypothyroidism.

Iron status

• Ferritin — the single most useful hair-loss marker after thyroid. Multiple dermatology groups suggest targeting ferritin above 40–70 ng/mL in women with active shedding, even though lab "normal" often starts at 15.
• CBC, serum iron, TIBC, transferrin saturation — to distinguish true iron deficiency from inflammation-driven low ferritin.

Androgens

• Total and free testosterone
• DHEA-S — adrenal androgen output
• SHBG — because free (bioavailable) androgen is what the follicle actually sees
• 17-hydroxyprogesterone — to screen for non-classic congenital adrenal hyperplasia in the right clinical picture
• Prolactin — elevated prolactin can drive both cycle changes and hair shedding

If PCOS is on the table, add a fasting glucose, fasting insulin, and HbA1c — insulin resistance amplifies ovarian androgen output.

Estrogen and reproductive axis (context-dependent)

• Estradiol, FSH, LH — especially in perimenopausal women, where a rising FSH and falling estradiol reshape the hair cycle.

Nutrient and metabolic cofactors

• Vitamin D (25-OH) — low levels are repeatedly associated with FPHL and telogen effluvium.
• Vitamin B12 and folate
• Zinc
• Comprehensive metabolic panel — baseline liver and kidney function matter if spironolactone or oral minoxidil is on the table.

{callout: The takeaway} Ferritin, TSH with free T4/T3, free testosterone with SHBG, DHEA-S, prolactin, and vitamin D form the minimum viable panel for female-pattern hair loss — anything less and you're guessing which driver you're treating.

How to read the results (tuned to your numbers)

Lab "normal" is not the same as "optimal for hair." A few interpretive rules that experienced clinicians actually use:

Ferritin between 15 and 40 ng/mL is technically normal but is repeatedly associated with active shedding. Many dermatologists treat toward 70+ ng/mL in symptomatic women, using oral iron with vitamin C, dosed to tolerance.

TSH above 2.5 mIU/L with symptoms (fatigue, cold intolerance, cycle changes, shedding) warrants a closer look at free T4, free T3, and antibodies — not a reflexive "you're normal."

Free testosterone or DHEA-S at the top of the range, especially with acne, midline thinning, or cycle irregularity, points toward an androgen-mediated pattern where spironolactone (or, off-label, low-dose oral finasteride or oral minoxidil) is more likely to help than topical monotherapy.

Low SHBG — often driven by insulin resistance, oral contraceptive discontinuation, or hypothyroidism — means free androgens are higher than total testosterone alone suggests. This is a common miss.

Prolactin above ~25 ng/mL deserves a repeat draw (fasting, no recent nipple stimulation or intense exercise) before further workup.

The number on the page is a starting point. The pattern across five or six markers is the actual diagnosis.

What changes when you actually have the panel (what actually changes)

With labs in hand, the treatment conversation stops being generic. A few examples of how the plan forks:

• Ferritin 22, TSH 3.8, TPO antibodies positive → this is not primarily an androgen problem. Correct iron, address thyroid, and shedding often improves substantially before any hair-specific drug is added.
• Free testosterone high-normal, DHEA-S elevated, SHBG low, irregular cycles → androgen-driven FPHL, likely PCOS-adjacent. Spironolactone (typical published titration range 50–200 mg/day), topical minoxidil, and metabolic work on insulin sensitivity become the backbone.
• Perimenopausal, FSH rising, estradiol falling, otherwise clean panel → the conversation shifts to whether hormone therapy is appropriate, plus topical minoxidil and consideration of low-dose oral minoxidil where indicated.
• Everything normal, recent stressor or illness 3–4 months ago → likely telogen effluvium, self-limited, and the plan is reassurance plus support, not lifelong therapy.

Same symptom. Four different plans. That's what the panel buys you.

Common workup mistakes (worth avoiding)

1. Checking TSH alone. Misses conversion issues and autoimmune thyroid disease. 2. Accepting ferritin of 20 as "normal." Technically in-range, functionally too low for a shedding scalp. 3. Ordering total testosterone without SHBG. Free androgen is what matters at the follicle. 4. Skipping prolactin. A five-dollar test that occasionally rewrites the whole diagnosis. 5. Starting spironolactone before confirming there's actually an androgen signal to treat. It can still help via receptor blockade, but you're flying blind on dose and expectations. 6. Assuming postpartum shedding needs a drug. Most resolves by 12 months; the workup is to rule out coexisting iron or thyroid issues.

When to run the panel — and when to re-run it

Baseline: at the first serious conversation about treatment, before starting spironolactone, oral minoxidil, oral finasteride, or hormone therapy for hair.

Repeat: 3 months after starting iron repletion (ferritin), 6–8 weeks after any thyroid medication change (TSH, free T4), and 3 months after starting spironolactone if there are tolerance concerns (potassium, basic metabolic panel).

Hair itself is a slow readout. The hair cycle means visible change from any intervention typically takes 4–6 months, sometimes longer. The labs are how you confirm the intervention is working long before the mirror does.

The bottom line

Female-pattern hair loss deserves the same diagnostic rigor as any other hormonally-mediated condition. A clinician who prescribes for hair without at minimum a thyroid, iron, androgen, and vitamin D picture in front of them is treating an average patient — not you.

The labs worth having before a serious protocol are not exotic, not expensive, and not optional if you want the plan to actually match the biology. Real labs, plain-English plan — that's the whole point.

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.